Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Niels C Pedersen, Yunjeong Kim, Hongwei Liu, Anushka C. Galasiti Kankanamalage, Chrissy Eckstrand, William C. Groutas, Michael Bannasch, Juliana M. Meadows, Kyeong Ok Chang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). Methods: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. Results: Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age. Conclusions and relevance: GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.

Original languageEnglish (US)
JournalJournal of Feline Medicine and Surgery
DOIs
StateAccepted/In press - Sep 1 2017

Fingerprint

Feline Infectious Peritonitis
feline infectious peritonitis
proteinase inhibitors
Protease Inhibitors
Cats
cats
remission
relapse
Recurrence
Therapeutics
kittens
3C proteases
antiviral agents
Tooth Eruption
stinging
nervous system diseases
alopecia
Alopecia

ASJC Scopus subject areas

  • Small Animals

Cite this

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. / Pedersen, Niels C; Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C.; Eckstrand, Chrissy; Groutas, William C.; Bannasch, Michael; Meadows, Juliana M.; Chang, Kyeong Ok.

In: Journal of Feline Medicine and Surgery, 01.09.2017.

Research output: Contribution to journalArticle

Pedersen, Niels C ; Kim, Yunjeong ; Liu, Hongwei ; Galasiti Kankanamalage, Anushka C. ; Eckstrand, Chrissy ; Groutas, William C. ; Bannasch, Michael ; Meadows, Juliana M. ; Chang, Kyeong Ok. / Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. In: Journal of Feline Medicine and Surgery. 2017.
@article{a3f617f8cf0a41ec8b12522af00be850,
title = "Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis",
abstract = "Objectives: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). Methods: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. Results: Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age. Conclusions and relevance: GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.",
author = "Pedersen, {Niels C} and Yunjeong Kim and Hongwei Liu and {Galasiti Kankanamalage}, {Anushka C.} and Chrissy Eckstrand and Groutas, {William C.} and Michael Bannasch and Meadows, {Juliana M.} and Chang, {Kyeong Ok}",
year = "2017",
month = "9",
day = "1",
doi = "10.1177/1098612X17729626",
language = "English (US)",
journal = "Journal of Feline Medicine and Surgery",
issn = "1098-612X",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

AU - Pedersen, Niels C

AU - Kim, Yunjeong

AU - Liu, Hongwei

AU - Galasiti Kankanamalage, Anushka C.

AU - Eckstrand, Chrissy

AU - Groutas, William C.

AU - Bannasch, Michael

AU - Meadows, Juliana M.

AU - Chang, Kyeong Ok

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objectives: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). Methods: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. Results: Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age. Conclusions and relevance: GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.

AB - Objectives: The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). Methods: Twenty cats from 3.3–82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial. Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP. GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg. Cats with neurologic signs were excluded from the study. Results: Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment. However, disease signs recurred 1–7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks. Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1–7 weeks of initial or repeat treatment(s). Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions. At the time of writing, seven cats were in disease remission. Five kittens aged 3.3–4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5–14 months (mean 11.2 months). A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376. The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period. Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss. There was retarded development and abnormal eruption of permanent teeth in cats treated before 16–18 weeks of age. Conclusions and relevance: GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=85042533541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042533541&partnerID=8YFLogxK

U2 - 10.1177/1098612X17729626

DO - 10.1177/1098612X17729626

M3 - Article

C2 - 28901812

AN - SCOPUS:85042533541

JO - Journal of Feline Medicine and Surgery

JF - Journal of Feline Medicine and Surgery

SN - 1098-612X

ER -